m6A RNA methylation: The latent string-puller in fibrosis

Area of Science:

• Biochemistry
• Molecular Biology
• Pathology

Background:

• Fibrosis involves abnormal extracellular matrix accumulation, posing a significant global health and economic burden.
• It is an age-related disease and the end-stage of many chronic inflammatory conditions.
• Current treatments for fibrosis are limited due to complex pathogenesis and unidentified key molecular targets.

Purpose of the Study:

• To review the mechanisms and functions of N6-methyladenosine (m6A) in various organ fibroses.
• To emphasize the universal and critical role of m6A in the pathogenesis of fibrosis.
• To explore the therapeutic potential of targeting m6A for fibrosis treatment.

Main Methods:

• Literature review focusing on m6A modifications and their involvement in fibrotic diseases.
• Analysis of existing evidence linking m6A to the pathogenesis of fibrosis across multiple organs.
• Synthesis of current understanding and future directions for m6A-based fibrosis therapies.

Main Results:

• N6-methyladenosine (m6A) is the most prevalent mRNA modification in mammals.
• Growing evidence indicates m6A actively participates in the development of fibrosis.
• m6A modification plays a universal and critical role in the pathogenesis of fibrosis.

Conclusions:

• m6A modification is deeply implicated in the pathogenesis of diverse fibrotic diseases.
• Targeting m6A pathways presents a promising avenue for novel anti-fibrotic therapies.
• Further research into m6A is essential for understanding and treating fibrosis effectively.